Technical appendix to "The Effect of Insurance in the First Three Months of Hemodialysis on Vascular Access"

APPENDIX A: Technical Specifications

Data Sources

Data came from the United States Renal Data System (USRDS), a registry with claims data for all patients with Medicare Parts A and B and ESKD. We used the CMS Medical Evidence Report (Form CMS-2728) to identify dialysis modality, vascular access, insurance coverage, pre-ESKD nephrology care, demographics, and comorbid conditions at dialysis onset. We obtained longitudinal insurance, treatment, and vascular access information from Medicare enrollment data and claims. Medicare claims have included the type of vascular access used at the end of each month since July 2010. We linked patient zip codes to the 2010 Census and 2012 American Community Survey and obtained dialysis facility-level data from annual facility surveys.

Identification of Vascular Access on Dialysis Claims

We used modifier codes on dialysis claims to identify the type of vascular access. The modifier code V5 indicated the use of a central venous catheter, V6 indicated the use of an arteriovenous graft, and V7 indicated the use of an arteriovenous fistula for that month of dialysis.¹

Identification of Hospitalizations due to Vascular Access Infections

To identify hospitalizations due to infected vascular access, we first isolated acute hospitalizations from Medicare inpatient claims. Individual claims do not constitute acute admissions for two reasons. First, the United States Renal Data System (USRDS) inpatient claims file also contains admissions to inpatient rehabilitation and long-term care hospitals. Second, transfers between hospitals are billed as separate claims and thus need to be grouped

into a single admission. Therefore, we used a previously described algorithm to isolate acute

inpatient stays and to group transfers into single admissions.²

We then identified the acute admissions that involved vascular access infections and

those that involved any infection. To identify vascular access infections, we took the array of

diagnosis codes (ICD-9 or International Classification of Diseases 9) and identified admissions

with a diagnosis code that matched one of the codes in Table S1. For admissions that involved

any infection, we matched diagnosis codes with the list in Table S2.

 Table S1: Diagnosis Codes Corresponding to Center Venous Catheter Infections

ICD-9 Diagnosis Codes		
996.62	Infection and Inflammatory Reaction due to other Vascular	
	Device, Implant, or Graft	
999.31	Other and unspecified infection due to central venous catheter	
999.32	Bloodstream infection due to central venous catheter	
999.33	Local infection due to central venous catheter	

Abbreviations: ICD-9 = International Classification of Diseases

Table S2: Diagnosis Codes Corresponding to Any Infection

ICD-9 Diagnosis Codes 001–134, 136, 254.1 320–325, 382–382.4, 383.0-383.2, 386.33, 386.35, 388.60 421–421.1, 422.0, 422.92–422.93, 460–466, 475–476.0, 478.21–478.24, 478.29, 480–489 510–511.1, 513, 519.01, 522.5, 522.7, 527.3, 528.3, 566–567.9, 569.5, 572–572.1, 573.1– 573.3, 575.10–575.12, 576.1, 590–590.9, 595–595.4, 597–597.89, 598.0, 599.0 601–601.9, 604–604.9, 607.1, 607.2, 608.0, 608.4, 611.0, 614–616.1, 616.3–616.4, 616.8, 670, 675, 680–686.9 706.0, 711–711.9, 728.0, 728.86, 729.39, 729.4, 730–730.3, 730.8–730.9, 790.7–790.8 995.9, 996.60–996.69, 997.62, 998.5, 999.3

Abbreviations: ICD-9 = International Classification of Diseases

Calculation of Relative Risks

Odds ratios from logistic regression can be difficult to interpret, since the corresponding relative risk is dependent on the baseline event rate. To make these estimates more tangible, we calculated the predicted probability that each patient used an arteriovenous (AV) fistula or graft at the end of month four under the scenarios that the patient had insurance or was uninsured. The point estimate for the average relative risk, then, is the average of the quotient of these predicted probabilities. To obtain 95% confidence intervals, we used a non-parametric bootstrap. We describe our method to compute bootstrapped 95% confidence intervals on multiple imputation data later in this Appendix.

More formally, we specified the following logistic regression model:

$$Y_i | \beta_0 + X_{insurance,i} \beta_{insurance} + X_{covariates,i} \beta_{covariates} + \varepsilon_i$$

Here, we defined the outcome (Y_i) as the outcome that patient i was using an AV fistula or graft at the end of month four. We modeled Y_i using a Bernoulli distribution and a logit link function. In this model, $X_{insurance,i}$ is a binary exposure variable that indicates if patient i has insurance (1 if patient i has Medicare or Medicaid depending on the cohort and 0 if patient i is uninsured), $X_{covariates,i}$ is a vector of all other covariates, $\beta_{insurance}$ and $\beta_{covariates}$ are the respective coefficients from the regression, β_0 is the intercept, and ε_i is the randomly distributed error term for patient i. We defined the estimated coefficients from this model as $\hat{\beta}_0$, $\hat{\beta}_{insurance}$, and $\hat{\beta}_{covariates}$.

For each patient in the cohort, we calculated the predicted probability that the patient used AV fistula or graft at the end of month four under the scenarios that the patient had insurance ($\hat{Y}_{i,insurnace}$) or was uninsured ($\hat{Y}_{i,uninsured}$). In other words, for each patient i:

$$\hat{Y}_{i,insurnace} = logit^{-1}(\hat{\beta}_0 + \hat{\beta}_{insurance} + X_{covariates,i}\hat{\beta}_{covariates})$$
$$\hat{Y}_{i,uninsured} = logit^{-1}(\hat{\beta}_0 + X_{covariates,i}\hat{\beta}_{covariates})$$

For a patient i, we defined the adjusted relative risk of using an AV fistula or graft at month 4 when patient i has insurance *versus* no insurance:

$$RR_i = \frac{\hat{Y}_{i,insurnace}}{\hat{Y}_{i,uninsured}}$$

and the average relative risk of patients with insurance versus those without insurance

$$\overline{RR} = \frac{1}{N} \sum_{i=1}^{N} RR_i$$

Estimating the Probability of AVF/AVG Use by Month 13

is:

Using logistic regression to estimate the probability of AVF or AVG use by month 13 would have introduced bias due to the high mortality rate in this population. To account for censoring, we employed a 2-step estimation procedure to obtain predicted probabilities. First, for each patient, we obtained the predicted probabilities of using a dialysis catheter at month 4, under the scenarios that the patient had insurance or was uninsured:

 $\widehat{\Pr}(\text{catheter at month } 4|\text{insured}) = 1 - \widehat{Y}_{i,\text{insurnace}}$

 $\widehat{\Pr}(\text{catheter at month } 4|\text{uninsured}) = 1 - \widehat{Y}_{i,\text{uninsured}}$

Next, we took patients still using a catheter at month 4 and estimated a parameterized survival model assuming an exponential survival function to determine the rate of switching from a catheter to an AVF or AVG, censoring for death. These regression estimates allowed us to estimate the probability of using a catheter at month 12 for each patient, *conditional* on using a catheter at month 4, for the scenarios that the patient had insurance or was uninsured:

 $\hat{Z}_{i,insurance} = \Pr(\text{catheter at month 12}|\text{catheter at month 4}, insured)$ $\hat{Z}_{i,uninsured} = \Pr(\text{catheter at month 12}|\text{catheter at month 4}, uninsured)$

Using Baye's rule, we then estimated the unconditional probability of using an AVF or AVG by month 12, for the scenarios that the patient had insurance or was insured:

 $\widehat{W}_{i,insurance} = \Pr(AVF/AVG \text{ by month } 12|\text{insured}) = 1 - \Pr(\text{catheter at month } 12|\text{insured})$

 $= 1 - \Pr(\text{catheter at month } 12|\text{catheter at month } 4, \text{insured})$

* Pr(catheter at month 4|insured) = $1 - \hat{Z}_{i,insurance} * (1 - \hat{Y}_{i,insurance})$

 $\widehat{W}_{i,uninsured} = \Pr(AVF/AVG \ by \ month \ 12|uninsured)$

= 1 - Pr(catheter at month 12|uninsured)

= 1 – Pr(catheter at month 12|catheter at month 4, uninsured)

* Pr(catheter at month 4|uninsured) = $1 - \hat{Z}_{i,uninsured} * (1 - \hat{Y}_{i,uninsured})$

The average relative risk for using an AVF or AVG by month 12 is then:

$$\overline{RR}_{month13} = \frac{1}{N} \sum_{i=1}^{N} \frac{\widehat{W}_{i,insurance}}{\widehat{W}_{i,uninsured}}$$

Multiple Imputation

Because we had high numbers of missing values for body mass index (BMI), hemoglobin, and albumin, we used multiple imputation for these covariates. Since all missing covariates were categorical variables, we imputed these variables using chained equations and a multinomial logistic regression model with the augmented-regression approach suggested by White *et al.* to avoid bias from perfect prediction of categorical variables.^{3–5} For each statistic, we calculated the point estimate and 95% confidence interval using Rubin's rules.⁶ Since these rules do not apply for bootstrapped confidence intervals, we used a different process to perform statistical inference on relative risks, which we describe below. We used a total of 10 imputations for each missing variable.

Statistical Inference using Bootstrap Confidence Intervals

We used non-parametric bootstrap 95% confidence intervals to assess if the relative risks were statistically significant. Schomaker and Heumann suggest that in order to obtain the

correct standard errors we should first draw b = 1, ..., B bootstrap samples from the original dataset *with* missing values, then perform $m_b = 1, ..., M_B$ imputations on each of the B bootstrapped datasets.⁷ The sampling-imputation process yields $B \times M_B$ bootstrapped-imputed datasets, and we can calculate a relative risk for each of these datasets: RR_{b,m_b} . To find confidence intervals, we first compute $RR_b = \frac{1}{M_B} \sum_{m_b} RR_{b,m_b}$, which is the mean of the "imputed" relative risks for each of the B bootstrapped datasets. We then take the 2.5% and 97.5% quantiles of RR_b . (Of note, we could simply take the 2.5% and 97.5% quantiles of all estimates RR_{b,m_b} for all b and m_b. Schomaker and Heumann suggest that this approach yields confidence intervals that are too wide). We again chose a total of ten imputations for each of the bootstrapped datasets (M_B = 10) and drew B = 250 bootstrapped samples.

Additional Analyses and Sensitivity Analyses

It is possible that for some patients AVFs or (to a lesser extent) AVGs were not ready for use by the end of the fourth dialysis month, due to delayed maturation or healing. To investigate this possibility, we performed the following sensitivity analyses:

- We modeled the likelihood of using an AVF or AVG by the end of the sixth dialysis month using a multivariable logistic regression. This is in contrast to our primary analysis, which examined the likelihood of using an AVF or AVG by the end of the fourth dialysis month.
- 2) We restricted our study population to patients receiving hemodialysis through a central venous catheter at the end of the fourth dialysis month, and we examined the time to switching from a central venous catheter to an AVF or AVG using a competing risks model. In our primary analysis, we used a traditional Cox regression. We also performed the following additional analyses to test model specifications:

6

3) We included patients with nephrology care prior to developing ESKD and

incorporated an indicator for whether a patient received such care.

4) We repeated all primary analyses using a complete case analysis.

None of our results changed materially in these sensitivity analyses (Table S11):

APPENDIX B: Supplemental Tables

In **Tables S3-S10**, we show the regression coefficients from the primary analyses and analyses of hospitalization involving vascular access infection. We then show results from secondary study aims and sensitivity analyses in **Table S11**.

Coveriete	OP	05% CI	P-
Covariate	UK	95% CI	value
Intercept	0.07	(0.03, 0.15)	***
Insurance			
No insurance		Reference	
Medicare	2.00	(1.26, 3.16)	**
Dual Eligible	1.13	(0.93, 1.38)	
Age	0.83	(0.47, 1.47)	
Age ²	1.63	(0.37, 7.26)	
Sex			
Female	0.69	(0.58, 0.80)	***
Male		Reference	
Race			
White		Reference	
Black	1.39	(1.15, 1.69)	***
Other	1.58	(1.09, 2.28)	*
Ethnicity			
Hispanic	1.34	(1.05, 1.71)	*
Employed	0.75	(0.50, 1.12)	
BMI (kg/m²)			
< 18.5	0.96	(0.62, 1.47)	
18.5 to < 30		Reference	
30 to < 40	1.05	(0.88, 1.25)	
≥ 40	0.98	(0.74, 1.28)	

Table S3: Logistic Regression Coefficients, Modeling Arteriovenous Fistula or Graft Use at Month 4, Medicare versus No Insurance, Multiple Imputation Analysis

Albumin (g/dL)			
< 2.5	0.65	(0.49, 0.87)	**
2.5 to < 3	0.91	(0.71, 1.16)	
3 to < 3.5	0.88	(0.70, 1.12)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	1.05	(0.82, 1.33)	
8 to < 9	1.03	(0.84, 1.25)	
9 to < 11		Reference	
≥ 11	1.00	(0.78, 1.28)	
Comorbidities			
Coronary Artery Disease	1.03	(0.84, 1.27)	
Congestive Heart Failure	0.92	(0.77, 1.09)	
Cancer	0.82	(0.61, 1.10)	
Hypertension	0.96	(0.76, 1.22)	
Chronic Obstructive Pulmonary Disease	0.81	(0.63, 1.04)	
Diabetes Mellitus	1.17	(0.99, 1.39)	
Peripheral Vascular Disease	0.82	(0.65, 1.04)	
Prior Cerebrovascular Accident	1.47	(1.17, 1.84)	**
Drug Dependence	1.05	(0.65, 1.71)	
Smoker	1.14	(0.85, 1.53)	
Patient institutionalized	0.85	(0.64, 1.13)	
Needs Assistance with ADLs and/or Inability			
to Transfer	0.81	(0.64, 1.03)	
Facility Characteristics			
Large Dialysis Organization	1.09	(0.91, 1.31)	
Facility is for-profit	0.90	(0.67, 1.22)	
Facility is hospital-based	1.22	(0.83, 1.78)	
Total Facility Patients per Year			
0 to 50	1.25	(1.01, 1.53)	*
51 to 100		Reference	
101 to 150	1.09	(0.89, 1.33)	
> 150	0.88	(0.69, 1.13)	
Full Time Patient to Nurse/Tech Ratio			
< 7		Reference	
≥7	1.05	(0.89, 1.23)	

Residence Characteristics

Urban	1.12	(0.94, 1.33)	
% Poverty in Zipcode			
< 15%		Reference	
15% to <25%	0.92	(0.74, 1.13)	
≥ 25%	0.88	(0.68, 1.14)	
% Less than High school Education in Zipc	ode		
< 15%		Reference	
15% to <30%	1.19	(0.97, 1.46)	
≥ 30%	1.44	(1.05, 1.97)	*
Year of Dialysis Start			
2010		Reference	
2011	1.01	(0.79, 1.29)	
2012	1.04	(0.81, 1.33)	
2013	1.34	(1.01, 1.79)	*
Season of Dialysis Start			
Winter		Reference	
Spring	1.29	(1.04, 1.59)	*
Summer	0.99	(0.80, 1.22)	
Fall	1.07	(0.85, 1.35)	

*** p < 0.001 ** p < 0.01 * p < 0.05

Note: Includes robust standard errors.

Covariato	OP	95% CI	P- Valuo
Covariate		3378 01	value
Intercept	0.07	(0.04, 0.10)	***
		(0.0.1, 0.1.0)	
Insurance			
No insurance		Reference	
Medicaid	1.27	(1.13, 1.43)	***
Age	0.90	(0.75, 1.09)	
Age ²	0.98	$(0.94 \ 1.03)$	
~9°	0.00	(0.01, 1.00)	
Sex			
Female	0.78	(0.69, 0.88)	***
Male		Reference	
Race			
White		Reference	
Black	1.17	(1.01, 1.35)	*
Other	1.44	(1.12, 1.85)	**
Ethnicity			
Hispanic	1 13	(0.95, 1.33)	
Thepartie	1.10	(0.00, 1.00)	
Employed	0.73	(0.61, 0.88)	***
BMI (kg/m²)			
< 18.5	0.83	(0.58, 1.19)	
18.5 to < 30		Reference	
30 to < 40	0.98	(0.86, 1.11)	
≥40	0.99	(0.82, 1.19)	
A H • 7 7 H \			
Albumin (g/dL)	0.70		4 4
< 2.5	0.76	(0.63, 0.93)	~~
2.5 to < 3	0.91	(0.76, 1.09)	
3 to < 3.5	0.86	(0.73, 1.02)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	0.99	(0.84, 1.16)	
8 to < 9	1.14	(0.97, 1.33)	
		()	

Table S4: Logistic Regression Coefficients, Modeling Arteriovenous Fistula or Graft Use at Month 4, Medicaid versus No Insurance, Multiple Imputation Analysis

9 to < 11		Reference	
≥ 11	1.07	(0.90, 1.29)	
Comorbidities			
Coronary Artery Disease	1.00	(0.80, 1.24)	
Congestive Heart Failure	1.07	(0.93, 1.23)	
Cancer	0.48	(0.29, 0.79)	**
Hypertension	1.22	(1.01, 1.47)	*
Chronic Obstructive Pulmonary Disease	1.05	(0.80, 1.38)	
Dishetes Mellitus	0.04	(0.02, 1.07)	
Diabetes Meinitus	0.94	(0.83, 1.07)	
Peripheral Vascular Disease	1.23	(0.97, 1.54)	
Prior Cerebrovascular Accident	1.15	(0.90, 1.46)	
Drug Dependence	0.95	(0.75, 1.20)	
Smoker	1.10	(0.92, 1.32)	
Patient institutionalized	0.73	(0.49, 1.07)	
to Transfer	0.95	(0.75, 1.21)	
		, , , , , , , , , , , , , , , , , , ,	
Facility Characteristics			
Large Dialysis Organization	1.27	(1.11, 1.46)	***
Facility is for-profit	0.90	(0.73, 1.11)	
Facility is hospital-based	1.22	(0.93, 1.61)	
Total Facility Patients per Vear			
0 to 50	1 00	(0.85, 1.18)	
51 to 100	1.00	(0.00, 1.10) Deference	
101 to 150	0 00		
101 10 150 > 160	0.09	(0.77, 1.03)	
> 150	0.95	(0.80, 1.12)	
Full Time Patient to Nurse/Tech Ratio			
< 7		Reference	
≥7	0.97	(0.86, 1.09)	
Posidonco Charactoristics			
Nesidence Unaracleristics	1 00	(0.87 1.14)	
Olban	1.00	(0.07, 1.14)	
% Poverty in Zipcode			
< 15%		Reference	
15% to <25%	1.00	(0.86, 1.16)	
≥ 25%	0.86	(0.72, 1.04)	
% Less than High school Education in Zipco	oae	Reference	

15% to <30% 1.05 (0.90, 1.21)	
≥ 30% 1.21 (0.99, 1.50)	
Year of Dialysis Start	
2010 Reference	
2011 1.18 (0.98, 1.42)	
2012 1.20 (0.99, 1.44)	
2013 1.41 (1.14, 1.74)	**
Season of Dialysis Start	
Winter Reference	
Spring 1.24 (1.06, 1.44)	**
Summer 1.00 (0.85, 1.17)	
Fall 0.98 (0.83, 1.16)	

*** p < 0.001 ** p < 0.01

* p < 0.05

Note: Includes robust standard errors.

			P-
Covariate	HR	95% CI	Value
Insurance			
No insurance		Reference	
Medicare	1.14	(0.94, 1.39)	
		, , ,	
Dual Eligible	1.03	(0.93, 1.14)	
	0.04		
Age	0.91	(0.69, 1.20)	
Age ²	1.54	(0.82, 2.89)	
Sex			
Female	0.91	(0.84, 0.98)	*
Male		Reference	
Race			
White		Reference	
Black	1.10	(1.00, 1.22)	
Other	1.41	(1.18, 1.68)	***
Ethnicity			
Hispanic	1 27	(1 13 1 44)	***
		(,	
Employed	1.13	(0.95, 1.33)	
BMI (kg/m²)			
< 18.5	0.82	(0.65, 1.04)	
18.5 to < 30		Reference	
30 to < 40	0.94	(0.86, 1.03)	
≥ 40	0.99	(0.87, 1.12)	
Albumin (g/dL)			
< 2.5	0.81	(0.71, 0.94)	**
2.5 to < 3	0.87	(0.76, 0.99)	*
3 to < 3.5	0.88	(0.77, 1.00)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	0.94	(0.83, 1.06)	
8 to < 9	0.92	(0.83, 1.02)	

Table S5: Cox Regression Coefficients, Modeling Time to Arteriovenous Fistula or GraftUse, Medicare versus No Insurance, Multiple Imputation Analysis

9 to < 11		Reference	
≥ 11	0.90	(0.79, 1.02)	
Comorbidities			
Coronary Artery Disease	0.92	(0.83, 1.02)	
Congestive Heart Failure	0.94	(0.86, 1.02)	
Cancer	0.85	(0.73, 0.99)	*
Hypertension	1.12	(0.99, 1.26)	
Chronic Obstructive Pulmonary Disease	0.94	(0.83, 1.05)	
Diabetes Mellitus	1.08	(1.00, 1.18)	
Peripheral Vascular Disease	1.07	(0.95, 1.20)	
Prior Cerebrovascular Accident	0.99	(0.87, 1.12)	
Drug Dependence	0.85	(0.65, 1.11)	
Smoker	1.08	(0.93, 1.24)	
Patient institutionalized	0.85	(0.73, 0.98)	*
Needs Assistance with ADLs and/or Inability	0.04	(0.74.0.04)	4 4 4
to Transfer	0.81	(0.71, 0.91)	~ ~ ~
Facility Characteristics	4.00		4 4 4
	1.30	(1.19, 1.43)	÷
Facility is for-profit	0.85	(0.73, 0.99)	^
Facility is nospital-based	0.91	(0.74, 1.12)	
Total Escility Datiants par Vaar			
0 to 50	1 09	(0.08.1.20)	
51 to 100	1.00	(0.90, 1.20) Deference	
101 to 150	1 02		
> 150	0.80	(0.32, 1.12) (0.70, 1.01)	
2 100	0.03	(0.73, 1.01)	
Full Time Patient to Nurse/Tech Ratio			
< 7		Reference	
>7	1 02	$(0.94 \ 1.10)$	
- /	1.02	(0.01, 1.10)	
Residence Characteristics			
Urban	1 00	(0.92, 1.09)	
		(0.02, 1.00)	
% Poverty in Zipcode			
< 15%		Reference	
15% to <25%	1.08	(0.98, 1.19)	
≥ 25%	1.03	(0.91, 1.17)	
		()	
% Less than High school Education in Zipc	ode		
< 15%		Reference	
15% to <30%	0.96	(0.87, 1.06)	

≥ 30%	1.07	(0.92, 1.25)	
Year of Dialysis Start			
2010		Reference	
2011	1.13	(1.00, 1.26)	*
2012	1.16	(1.03, 1.31)	*
2013	1.16	(0.99, 1.37)	
Season of Dialysis Start			
Winter		Reference	
Spring	1.02	(0.91, 1.14)	
Summer	1.00	(0.90, 1.11)	
Fall	1.08	(0.97, 1.20)	

*** p < 0.001 ** p < 0.01 * p < 0.05

Covariato	ЦВ	95% CI	P- Valuo
Covariate	пк	95 /8 CI	value
Insurance			
No insurance		Reference	
Medicaid	1.00	(0.95, 1.05)	
Age	0.90	(0.83, 0.97)	**
Age ²	0.97	(0.96, 0.99)	**
Sex	0.02	(0, 70, 0, 97)	***
Female	0.83	(0.79, 0.87)	
Male		Relefence	
Race			
White		Reference	
Black	1.01	(0.95, 1.08)	
Other	1.22	(1.09, 1.36)	***
Ethnicity			
Hispanic	1.12	(1.05, 1.20)	**
Freelowed	0.00	(0.02.1.06)	
Επριογέα	0.99	(0.93, 1.06)	
BMI (ka/m²)			
< 18.5	0.91	(0.78, 1.07)	
18.5 to < 30	••••	Reference	
30 to < 40	0.97	(0.92, 1.02)	
≥ 40	1.04	(0.97, 1.13)	
Albumin (g/dL)			
< 2.5	0.90	(0.83, 0.98)	*
2.5 to < 3	0.94	(0.87, 1.02)	
3 to < 3.5	0.95	(0.88, 1.02)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	1.01	(0.95, 1.08)	
- 8 to < 9	0.99	(0.93, 1.06)	
9 to < 11		Reference	
≥ 11	0.98	(0.90, 1.06)	

Table S6: Cox Regression Coefficients, Modeling Time to Arteriovenous Fistula or GraftUse, Medicaid versus No Insurance, Multiple Imputation Analysis

Comorbidities			
Coronary Artery Disease	0.99	(0.90, 1.10)	
Congestive Heart Failure	0.94	(0.89, 1.00)	
Cancer	0.74	(0.62, 0.88)	***
Hypertension	1.15	(1.07, 1.24)	***
Chronic Obstructive Pulmonary Disease	1.06	(0.94, 1.19)	
Diabetes Mellitus	0.99	(0.94, 1.05)	
Peripheral Vascular Disease	0.92	(0.83, 1.03)	
Prior Cerebrovascular Accident	0.96	(0.86, 1.07)	
Drug Dependence	0.97	(0.88, 1.07)	
Smoker	1.03	(0.95, 1.11)	
Patient institutionalized	0.89	(0.76, 1.04)	
Needs Assistance with ADLs and/or Inability	0.04		***
to transier	0.84	(0.75, 0.93)	
Facility Characteristics			
Large Dialysis Organization	1.22	(1.15, 1.29)	***
Facility is for-profit	0.96	(0.88, 1.05)	
Facility is hospital-based	0.96	(0.85, 1.09)	
Total Facility Patients per Year			
0 to 50	0.99	(0.93, 1.06)	
51 to 100		Reference	
101 to 150	0.96	(0.91, 1.02)	
> 150	0.96	(0.90, 1.03)	
Full Time Patient to Nurse/Tech Ratio			
< 7		Reference	
≥7	1.04	(0.99, 1.09)	
		(,	
Residence Characteristics			
Urban	0.95	(0.89, 1.00)	
9/ Deventuin Zineede			
		Deference	
< 15%	1 0 2		
15% LU <25%	1.03	(0.97, 1.10)	
23%	1.01	(0.94, 1.09)	
% Less than High school Education in Zipc	ode		
< 15%		Reference	
15% to <30%	1.01	(0.95, 1.07)	
≥ 30%	1.02	(0.93, 1.12)	

Year of Dialysis Start		
2010		Reference
2011	1.04	(0.97, 1.12)
2012	1.07	(0.99, 1.15)
2013	1.09	(0.99, 1.20)
Season of Dialysis Start		
Winter		Reference
Spring	1.04	(0.98, 1.11)
Summer	1.03	(0.97, 1.11)
Fall	1.00	(0.93, 1.07)

*** p < 0.001 ** p < 0.01 * p < 0.05

			P-
Covariate	HR	95% CI	Value
Insurance			
No insurance		Reference	
Medicare	0.61	(0.37, 1.00)	*
Dual Eligible	1.05	(0.85, 1.29)	
			d. d.
Age	2.55	(1.37, 4.74)	**
Age ²	0.64	(0.12, 3.27)	
Sex	4.40	(4.00.4.40)	
Female	1.19	(1.00, 1.42)	
Male		Reference	
Page			
		Deference	
White	0.00	Reference	
Black	0.98	(0.79, 1.21)	
Other	0.82	(0.52, 1.31)	
Ethnicity			
Hispanic	0.84	(0.62, 1.15)	
lispanic	0.04	(0.02, 1.13)	
Employed	0 79	(1.32, 0.48)	
	0.1.0	(1.02, 0110)	
BMI (ka/m²)			
< 18.5	0.51	(0.28, 0.95)	*
18.5 to < 30		Reference	
30 to < 40	1.02	(0.83, 1.24)	
≥ 40	1.33	(1.03, 1.72)	*
		(, ,	
Albumin (g/dL)			
< 2.5	1.39	(1.06, 1.83)	*
2.5 to < 3	1.14	(0.84, 1.54)	
3 to < 3.5	1.30	(0.98, 1.72)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	0.91	(0.70, 1.18)	
8 to < 9	1.11	(0.90, 1.37)	

Table S7: Cox Regression Coefficients, Modeling Time to First Hospitalization Involving Vascular Access Infection, Medicare versus No Insurance, Multiple Imputation Analysis

9 to < 11		Reference	
≥ 11	0.88	(0.65, 1.18)	
Comorbidities			
Coronary Artery Disease	1.12	(0.90, 1.39)	
Congestive Heart Failure	1.06	(0.87, 1.28)	
Cancer	0.90	(0.65, 1.24)	
Hypertension	0.85	(0.66, 1.09)	
Chronic Obstructive Pulmonary Disease	1.29	(1.03, 1.63)	*
Diabetes Mellitus	0.98	(0.81, 1.18)	
Peripheral Vascular Disease	0.87	(0.67, 1.12)	
Prior Stroke	1.19	(0.93, 1.51)	
Drug Dependence	0.62	(0.30, 1.28)	
Smoker	0.84	(0.59, 1.19)	
Patient institutionalized	1.63	(1.25, 2.13)	***
Needs Assistance with ADLs and/or Inability			
to Transfer	1.09	(0.85, 1.40)	
Facility Characteristics			
Large Dialysis Organization	0.97	(0.79, 1.18)	
Facility is for-profit	1.39	(0.96, 2.01)	
Facility is hospital-based	1.09	(0.70, 1.72)	
Total Facility Patients per Year			
0 to 50	1.01	(0.80, 1.27)	
51 to 100		Reference	
101 to 150	0.99	(0.79, 1.24)	
> 150	1.18	(0.91, 1.54)	
Full Time Defient to Nurse/Tech Defie			
rull time Patient to Nurse/Tech Ratio		Deference	
	0 00		*
21	0.62	(0.96, 0.69)	
Residence Characteristics			
l Irhan	1 08	(1 32 0 89)	
orban	1.00	(1.02, 0.00)	
% Poverty in Zipcode			
< 15%		Reference	
15% to <25%	1.10	(0.87, 1.40)	
≥ 25%	1.13	(0.85, 1.51)	
		(0.00, 1.01)	
% Less than High school Education in Zipo	ode		
< 15%		Reference	
15% to <30%	1.07	(0.85, 1.35)	

≥ 30%	0.95	(0.67, 1.36)	
Year of Dialysis Start			
2010		Reference	
2011	0.82	(0.65, 1.05)	
2012	0.77	(0.60, 0.98)	*
2013	0.68	(0.48, 0.97)	*
Season of Dialysis Start			
Winter		Reference	
Spring	0.82	(0.63, 1.05)	
Summer	1.06	(0.84, 1.33)	
Fall	0.93	(0.73, 1.18)	

*** p < 0.001 ** p < 0.01 * p < 0.05

Covariate	HR	95% CI	P- Value
Insurance			
No insurance		Reference	
Medicaid	1.11	(0.99, 1.23)	
Age	0.83	(0.78, 0.89)	***
Age ²	0.98	(0.94, 1.02)	
Sex		<i></i>	
Female	1.12	(1.00, 1.25)	*
Male		Reference	
Race			
White		Reference	
Black	1.00	(0.88, 1.15)	
Other	0.82	(0.62, 1.10)	
Ethnicity			
Hispanic	0 00	(0.84 1.18)	
nopulio	0.00	(0.04, 1.10)	
Employed	0.90	(0.76, 1.07)	
BMI (kg/m ²)			
< 18.5	0.66	(0.44, 0.98)	*
18.5 to < 30	4.04	Reference	**
30 10 < 40 > 40	1.21 1.30	(1.07, 1.37) (1.10, 1.54)	**
2 40	1.50	(1.10, 1.54)	
Albumin (g/dL)			
< 2.5	1.33	(1.12, 1.59)	**
2.5 to < 3	0.96	(0.79, 1.18)	
3 to < 3.5	1.00	(0.83, 1.21)	
≥ 3.5		Reference	
Hemoglobin category (g/dl)			
< 8	1.11	(0.95, 1.29)	
8 to < 9	1.07	(0.92, 1.25)	
9 to < 11		Reference	
≥ 11	1.01	(0.83, 1.22)	

Table S8: Cox Regression Coefficients, Modeling Time to First Hospitalization for Involving Vascular Access Infection, Medicaid *versus* No Insurance, Multiple Imputation Analysis

Comorbidities			
Coronary Artery Disease	1.08	(0.88, 1.32)	
Congestive Heart Failure	1.03	(0.90, 1.18)	
Cancer	1.17	(0.82, 1.66)	
Hypertension	1.12	(0.94, 1.33)	
Chronic Obstructive Pulmonary Disease	0.98	(0.76, 1.26)	
Diabetes Mellitus	1.06	(0.94, 1.20)	
Peripheral Vascular Disease	1.18	(0.96, 1.45)	
Prior Stroke	1.07	(0.85, 1.35)	
Drug Dependence	1.41	(1.16, 1.72)	***
Smoker	1.04	(0.88, 1.23)	
Patient institutionalized	1.06	(0.78, 1.44)	
Needs Assistance with ADLs and/or Inability			
to Transfer	1.11	(0.90, 1.37)	
Facility Characteristics			
Large Dialysis Organization	0.99	(0.87, 1.12)	
Facility is for-profit	1.27	(1.03, 1.58)	*
Facility is hospital-based	1.23	(0.94, 1.61)	
Total Facility Patients per Year			
0 to 50	0.83	(0.70, 0.97)	*
51 to 100		Reference	
101 to 150	0.88	(0.77, 1.01)	
> 150	0.94	(0.81, 1.09)	
Full Time Patient to Nurse/Tech Ratio			
< 7		Reference	
≥7	0.99	(0.89, 1.10)	
Residence Characteristics			
Urban	0.98	(0.86, 1.12)	
% Poverty in Zincode			
< 15%		Reference	
15% to <25%	1 07	(0.92, 1.25)	
≥ 25%	1.19	(0.99, 1.42)	
	_		
% Less than High school Education in Zipc	ode	Deference	
15% to <30%	1 00		
> 30%	1.00	(0.00, 1.10) (0.82, 1.25)	
≤ JU /0	1.01	(0.02, 1.23)	

Year of Dialysis Start			
2010		Reference	
2011	0.96	(0.82, 1.12)	
2012	0.84	(0.72, 0.99)	*
2013	0.74	(0.60, 0.92)	**
Season of Dialysis Start			
Winter		Reference	
Spring	0.92	(0.79, 1.06)	
Summer	0.88	(0.75, 1.02)	
Fall	0.86	(0.74, 1.00)	*

*** p < 0.001 ** p < 0.01 * p < 0.05

Covariato	ЦВ	95% CI	P- Valuo
Covallate	пк	95 /8 CI	value
Insurance			
No insurance		Reference	
Medicare	0.93	(0.71, 1.22)	
Dual Eligible	1.06	(0.94, 1.18)	
A.r.o.	1 62	(1 10 0 05)	**
Age	1.03	(1.18, 2.25)	
Age ²	0.70	(0.29, 1.71)	
Sex			
Female	1.15	(1.05, 1.27)	**
Male		Reference	
-			
		Deference	
Black	0.84	(0.75, 0.94)	**
Other	0.04	(0.73, 0.94) (0.54, 0.91)	**
	0110	(0101, 0101)	
Ethnicity			
Hispanic	0.85	(0.72, 0.99)	*
Employed	0.81	(0.63, 1.06)	
BMI (ka/m²)			
< 18.5	1.01	(0.79, 1.29)	
18.5 to < 30		Reference	
30 to < 40	0.97	(0.87, 1.08)	
≥ 40	1.03	(0.89, 1.20)	
Albumin (a/dl)			
	1 38	(1 18 1 62)	***
2.5 2.5 to < 3	1 16	(0.99, 1.36)	
3 to < 3.5	1.10	(0.92, 1.31)	
≥ 3.5		Reference	
Hemoglobin category (g/dL)			
< 8	0.91	(0.79, 1.06)	
8 to < 9	1.01	(0.89, 1.14)	

Table S9: Cox Regression Coefficients, Modeling Time to First Hospitalization Involving Any Infection, Medicare versus No Insurance, Multiple Imputation Analysis

9 to < 11		Reference	
≥ 11	0.94	(0.82, 1.09)	
Comorbidities			
Coronary Artery Disease	1.01	(0.89, 1.13)	
Congestive Heart Failure	1.11	(1.01, 1.23)	*
Cancer	1.23	(1.06, 1.43)	**
Hypertension	0.94	(0.81, 1.08)	
Chronic Obstructive Pulmonary Disease	1.36	(1.20, 1.54)	***
Diabetes Mellitus	1.09	(0.98, 1.20)	
Peripheral Vascular Disease	1.07	(0.94, 1.22)	
Prior Stroke	1.23	(1.08, 1.41)	**
Drug Dependence	1.17	(0.86, 1.58)	
Smoker	0.93	(0.78, 1.11)	
Patient institutionalized	1.32	(1.14, 1.53)	***
Needs Assistance with ADLs and/or Inability			
to Transfer	1.24	(1.09, 1.42)	**
Facility Characteristics			
Large Dialysis Organization	0.98	(0.88, 1.09)	
Facility is for-profit	0.98	(0.82, 1.17)	
Facility is hospital-based	0.95	(0.76, 1.20)	
Total Facility Patients per Year			
0 to 50	0.89	(0.78, 1.01)	
51 to 100		Reference	
101 to 150	0.97	(0.86, 1.10)	
> 150	1.07	(0.93, 1.24)	
Full Times Defined to Name (Task Defin			
Full Time Patient to Nurse/Tech Ratio		Deference	
< /	0.05	Reference	
21	0.95	(0.87, 1.05)	
Residence Characteristics			
	1 1 1	(1 00 1 22)	
Orban	1.11	(1.00, 1.23)	
% Poverty in Zincode			
		Deference	
15% to <25%	1 05		
> 25%	1.00	(0.95, 1.19) (0.95, 1.29)	
	1.11	(0.33, 1.28)	
% Less than High school Education in Zipco	de		
< 15%		Reference	
15% to <30%	1.02	(0.90, 1.15)	
		(

≥ 30%	0.90	(0.74, 1.08)
Year of Dialysis Start		
2010		Reference
2011	0.97	(0.84, 1.11)
2012	1.01	(0.88, 1.16)
2013	0.89	(0.74, 1.08)
Season of Dialysis Start		
Winter		Reference
Spring	1.04	(0.91, 1.18)
Summer	1.08	(0.95, 1.22)
Fall	1.01	(0.88, 1.15)

*** p < 0.001 ** p < 0.01 * p < 0.05

		P.
Covariate HR	95% CI	Value
Insurance		
No insurance	Reference	
Medicaid 1.21	(1 13 1 30)	***
	(,)	
Age 0.94	(0.90, 0.97)	***
Age ² 0.99	(0.97, 1.02)	
	(0.07, 1.02)	
Sex		
Female 1 26	(1 18 1 36)	***
Male	Reference	
Race		
White	Reference	
Black 0.88	(0.81, 0.96)	**
Other 0.74	(0.62, 0.88)	***
	(0:02, 0:00)	
Ethnicity		
Hispanic 0.81	(0.73, 0.90)	***
	(
Employed 0.86	(0.77, 0.97)	*
BMI (ka/m²)		
< 18.5 0.91	(0.74, 1.12)	
18.5 to < 30	Reference	
30 to < 40 0.95	(0.87, 1.03)	
≥ 40 0.95	(0.85, 1.07)	
	(0.00,)	
Albumin (g/dL)		
< 2.5 1.68	(1.49, 1.89)	***
2.5 to < 3 1.25	(1.10, 1.41)	***
3 to < 3.5 1.14	(1.01, 1.28)	*
≥ 3.5	Reference	
Hemoglobin category (g/dL)		
< 8 0.95	(0.86, 1.05)	
8 to < 9 0.98	(0.89, 1.08)	
9 to < 11	Reference	
≥ 11 0.96	(0.85, 1.07)	

Table S10: Cox Regression Coefficients, Modeling Time to First Hospitalization Involving Any Infection, Medicaid versus No Insurance, Multiple Imputation Analysis

Comorbidities			
Coronary Artery Disease	1.06	(0.93, 1.20)	
Congestive Heart Failure	1.11	(1.02, 1.20)	*
Cancer	1.45	(1.19, 1.77)	***
Hypertension	0.91	(0.82, 1.00)	
Chronic Obstructive Pulmonary Disease	1.22	(1.06, 1.42)	**
Diabetes Mellitus	1.18	(1.09, 1.28)	***
Peripheral Vascular Disease	1.25	(1.10, 1.42)	***
Prior Stroke	1.11	(0.97, 1.28)	
Drug Dependence	1.54	(1.36, 1.75)	***
Smoker	0.99	(0.89, 1.10)	
Patient institutionalized	1.08	(0.90, 1.30)	
Needs Assistance with ADLs and/or Inability	1 04	(1 00 1 11)	**
to transler	1.24	(1.09, 1.41)	
Facility Characteristics			
Large Dialysis Organization	0 97	(0.90, 1.06)	
Facility is for-profit	1.09	(0.96, 1.24)	
Facility is hospital-based	1.12	(0.95, 1.33)	
		(0.00, 1.00)	
Total Facility Patients per Year			
0 to 50	0.92	(0.83, 1.02)	
51 to 100		Reference	
101 to 150	0.93	(0.85, 1.01)	
> 150	0.96	(0.87, 1.06)	
Full Time Patient to Nurse/Tech Ratio		_ /	
< 7		Reference	
≥7	0.98	(0.91, 1.05)	
Decidence Characteristics			
	1.05	(0,07,1,14)	
Orban	1.05	(0.97, 1.14)	
% Poverty in Zipcode			
< 15%		Reference	
15% to <25%	1 06	(0.96, 1.16)	
≥ 25%	1.12	(1.00, 1.25)	
		(1.00, 1.20)	
% Less than High school Education in Zipo	code		
< 15%		Reference	
15% to <30%	0.98	(0.90, 1.07)	
≥ 30%	0.98	(0.86, 1.12)	

Year of Dialysis Start					
2010	Reference				
2011	0.95	(0.86, 1.05)			
2012	0.94	(0.85, 1.04)			
2013	0.79	(0.69, 0.90)	***		
Season of Dialysis Start					
Winter	Reference				
Spring	0.96	(0.87, 1.06)			
Summer	0.97	(0.88, 1.07)			
Fall	0.97	(0.88, 1.07)			

*** p < 0.001 ** p < 0.01 * p < 0.05

	Medicare			Medicaid		
Sensitivity Analyses	RR or HR	95% CI	p-value	RR or HR	95% CI	p-value
RR of AVF/AVG at month 4						
Main Analysis	1.63	1.14, 2.43	< 0.001	1.23	1.12, 1.38	< 0.001
Complete Case Analysis	1.75	1.08, 2.78	0.024	1.19	1.06, 1.36	< 0.001
RR by month 6	1.54	1.10, 2.18	0.013	1.24	1.13, 1.35	< 0.001
Including pre-ESKD nephrology care	1.84	1.38, 2.53	< 0.001	1.50	1.39, 1.61	< 0.001
Time to switching to AVF/AVG after r	nonth 4					
Main Analysis	1.17	0.97, 1.42	0.11	1.01	0.96, 1.06	0.73
Complete Case Analysis	1.09	0.86, 1.37	0.49	1.00	0.94, 1.06	0.97
Competing Risks Model	1.11	0.92, 1.35	0.27	0.99	0.94, 1.04	0.79
Including pre-ESKD nephrology care	1.12	0.97, 1.29	0.12	1.01	0.97, 1.06	0.60
RR of AVF/AVG at month 13						
Main Analysis	1.11	1.01, 1.22	0.040	1.01	1.00, 1.04	0.20
Complete Case Analysis	1.07	0.96, 1.20	0.23	1.01	0.99, 1.03	0.52
Including pre-ESKD nephrology care	1.14	1.06, 1.21	< 0.001	1.05	1.03, 1.07	< 0.001

Table S11: Results of Secondary and Sensitivity Analyses

Abbreviations: RR = relative risks. HR = hazard ratio, AVF = arteriovenous fistula, AVG = arteriovenous graft, ESKD = end-stage kidney disease

APPENDIX REFERENCES

1. Noridian Healthcare Solutions. Modifers. (2018). Available at:

https://med.noridianmedicare.com/web/jfa/topics/modifiers. (Accessed: 28th July 2018)

- 2. Lin, E., Kurella Tamura, M., Montez-Rath, M. E. & Chertow, G. M. Re-evaluation of rehospitalization and rehabilitation in renal research. *Hemodial. Int.* **21**, 422–429 (2017).
- Azur, M. J., Stuart, E. A., Frangakis, C. & Leaf, P. J. Multiple Imputation by Chained Equations: What is it and how does it work? *Int. J. Methods Psychiatr. Res.* 20, 40–49 (2011).
- Montez-Rath, M. E., Winkelmayer, W. C. & Desai, M. Addressing Missing Data in Clinical Studies of Kidney Diseases. *Clin. J. Am. Soc. Nephrol.* 9, 1328–1335 (2014).
- White, I. R., Daniel, R. & Royston, P. Avoiding bias due to perfect prediction in multiple imputation of incomplete categorical variables(). *Comput. Stat. Data Anal.* 54, 2267–2275 (2010).
- 6. Rubin, D. B. Multiple Imputation for Nonresponse in Surveys. (John Wiley & Sons, 1987).
- Schomaker, M. & Heumann, C. Bootstrap Inference when Using Multiple Imputation. *ArXiv* Prepr. ArXiv160207933 (2016).